Accretion/dilution analysis measures whether an acquisition increases or decreases the buyer’s earnings per share, usually on a pro forma first-year or second-year basis. A deal is accretive when pro forma EPS exceeds standalone EPS, and dilutive when it falls short. For finance professionals, the payoff is practical: cleaner deal models, sharper board materials, fewer surprises in investor messaging, and better questions when a transaction depends on financing, synergies, or accounting treatment.
That distinction matters at the start. Accretion/dilution analysis is an accounting outcome, not proof of value creation. A buyer can create apparent accretion through cheap debt, a low-tax target, or adjusted earnings that exclude the costs needed to achieve synergies. None of that proves the buyer paid the right price, improved its credit profile, or strengthened its competitive position.
The core formula is simple. Pro forma EPS equals pro forma net income available to common shareholders divided by pro forma diluted weighted-average shares outstanding. The difficulty sits inside “pro forma,” because small changes in financing mix, purchase accounting, tax treatment, or synergy timing can move a deal from mildly dilutive to mildly accretive without changing the underlying economics.
Practitioners should separate three versions of the metric. GAAP EPS accretion includes purchase accounting and reported transaction effects. Adjusted EPS accretion excludes selected items such as amortization, restructuring, integration costs, or stock compensation, and is often the version marketed to investors. Cash EPS accretion adds back non-cash amortization, which can help assess debt capacity but can overstate economics if maintenance capex, customer attrition, or integration cash costs are ignored.
The analysis should not replace valuation work. A deal can be accretive while destroying value if the buyer pays a high multiple for low-growth earnings and accepts heavy integration risk. Conversely, year-one dilution from amortization or equity issuance does not rule out long-term value creation. The investment committee question is not only “is the deal accretive?” It is “what assumptions are required for accretion, and are those assumptions supported elsewhere in the underwriting case?”
A clean model starts with the buyer’s standalone net income. It then adds the target’s after-tax earnings, normalized for one-time items, and subtracts incremental interest expense, foregone interest income on cash used, and new depreciation and amortization from purchase accounting step-ups. It also adds credible operating synergies, net of dis-synergies, and applies the tax effect of all pre-tax adjustments.
Each line should trace to a diligence source. The best bridges tie assumptions to a financing term sheet, a purchase accounting estimate, a management forecast, or a quality of earnings report. If a line cannot be sourced, label it as an assumption and sensitize it.
A cash deal usually leaves the buyer’s share count unchanged, apart from equity awards or convertibles affected by the transaction. A stock deal increases shares issued to the seller. A mixed deal requires both adjustments. In stock deals, the buyer’s trading multiple becomes acquisition currency. A buyer trading at 20x earnings and issuing stock to acquire earnings at 10x is arithmetically more likely to show accretion before synergies, because it is selling expensive equity and buying cheaper earnings.
Financing mix is often the fastest lever in an accretion/dilution model. Debt-funded acquisitions tend to be accretive when the target’s earnings yield exceeds the after-tax cost of debt. For example, a target acquired at 15x earnings has a 6.7% earnings yield. Debt at a 4% after-tax cost clears that threshold. Debt at a 7% after-tax cost does not, so the deal needs synergies or growth before EPS improves.
Stock-funded acquisitions depend on relative earnings yields. They are more likely to be accretive when the target’s earnings yield exceeds the buyer’s earnings yield. Cash-funded acquisitions look attractive when the target’s earnings yield exceeds the after-tax yield on cash deployed, but that ignores opportunity cost. Cash could fund buybacks, debt repayment, or organic investment. A deal can beat the standalone case and still lose to the next-best use of capital.
Debt-funded accretion should always be paired with credit metrics. Leverage, interest coverage, fixed-charge coverage, and deleveraging schedules matter more than first-year EPS if the target is cyclical, contractually weak, or capital-intensive. For private credit investors, payment-in-kind interest, original issue discount, call protection, and amendment fees can weaken cash flow even when adjusted EPS looks stable. This is where EPS work should connect directly to debt financing metrics.
Purchase accounting often determines whether the reported answer looks clean. Under acquisition accounting, the buyer records identifiable assets and liabilities at fair value and recognizes goodwill for the residual purchase price. This creates new amortization charges that did not exist in the target’s historical financials.
Intangible amortization is usually the most important EPS item. Customer relationships, developed technology, trade names, and backlog can create material charges. Goodwill is not amortized under US GAAP or IFRS, but it is tested for impairment. As a result, a deal can be dilutive on GAAP EPS while accretive on cash EPS, a gap advisers often emphasize in deal marketing.
Inventory step-up can also distort early periods. If inventory is marked to fair value at closing, the step-up flows through cost of goods sold as inventory is sold, reducing reported gross margin for a limited period. Advisers often exclude it from adjusted EPS, but it can still affect covenant EBITDA definitions, earnouts, and management incentives. Before purchase accounting diligence is complete, the model should show ranges for amortization, inventory step-up, deferred taxes, and depreciation. For deeper accounting context, the related issue is purchase price allocation.
A numerical bridge shows why the headline can mislead. Assume a public buyer has $500 million of net income and 100 million diluted shares, giving standalone EPS of $5.00. It acquires a target for $1.2 billion, funded with $600 million of debt and $600 million of stock. At a $50 share price, the buyer issues 12 million shares. Incremental pre-tax interest is $42 million, pre-tax amortization is $20 million, and the tax rate is 25%.
The pre-synergy earnings bridge produces $543.5 million of pro forma net income. The share bridge produces 112 million pro forma shares. Pro forma EPS is $4.85, or about 3% dilutive. If the buyer adds $30 million of pre-tax cost synergies, worth $22.5 million after tax, pro forma net income rises to $566 million and EPS becomes $5.05, or about 1% accretive.
The real conclusion is that EPS depends on synergies. Without them, the deal is dilutive. With them, it is accretive. The more useful output is breakeven synergies. In this example, the buyer needs $560 million of net income to maintain $5.00 of EPS on 112 million shares. The after-tax shortfall is $16.5 million, implying $22 million of required pre-tax synergies at a 25% tax rate.
Breakeven synergies give an IC memo a sharper risk test. If management underwrites $30 million and breakeven is $22 million, the cushion is only $8 million before implementation costs, dis-synergies, timing delays, and attrition. If breakeven is $5 million and procurement savings alone are $25 million, the EPS risk is far lower. The model must also separate run-rate synergies from realized synergies. Year-one EPS should include only savings actually achieved in year one, not year-three targets. This links directly to synergy realization.
Adjusted EPS can be useful, but it can also obscure real costs. Excluding transaction costs and inventory step-up is usually reasonable. Excluding restructuring expenses tied to a specific integration event may also be defensible. The problem starts when the buyer excludes amortization, integration costs, stock compensation, retention payments, and recurring restructuring while still calling the result a clean earnings measure.
Every adjusted EPS case should reconcile to free cash flow per share. That reconciliation should include cash taxes, cash interest, integration cash costs, restructuring payments, capex, working capital, and deferred revenue haircut effects. If adjusted EPS is accretive but free cash flow per share is dilutive for two or three years, the case is weak for creditors and long-duration shareholders.
A practical review should focus on the assumptions that control the public earnings narrative. A junior banker, corporate development associate, or credit analyst should be able to answer the following before a committee meeting:
Common model failures usually bias results toward accretion. Teams import unnormalized target earnings, double-count synergies across operating forecasts and synergy lines, ignore dis-synergies such as customer loss or stranded costs, apply one blended tax rate to every adjustment, and use exclusions that will recur for several years. Each assumption should be auditable to a specific source.
Accretion/dilution analysis belongs in every M&A deal model, but it has a limited role. It explains how a transaction affects the public EPS narrative, not whether the buyer created durable value. Finance professionals should use it to stress-test synergy timing, adjusted EPS exclusions, purchase accounting ranges, financing sensitivity, and opportunity cost. The career-relevant habit is simple: separate arithmetic accretion from value creation in every model, IC memo, and board discussion.
P.S. – Check out our Premium Resources for more valuable content and tools to help you advance your career.
